📊 VMD Key Takeaways
Is Viemed Healthcare, Inc.. (VMD) a Good Investment?
VIEMED demonstrates solid 20.5% YoY revenue growth, but fundamentals are challenged by thin operating margins (5.7%), weak return on equity (1.8%), and severely constrained free cash flow generation (1.8% FCF margin). The capital-intensive business model and low profitability metrics suggest limited financial flexibility despite a healthy balance sheet.
Viemed Healthcare, Inc.. Key Strengths (VMD)
- Strong revenue growth at 20.5% YoY indicates solid market demand
- Excellent balance sheet with minimal leverage (0.06x Debt/Equity) and adequate liquidity (1.22x current ratio)
- Healthy gross margin of 56.8% demonstrates reasonable unit economics and pricing power
VMD Stock Risks: Viemed Healthcare, Inc.. Investment Risks
- Severely compressed profitability: operating margin of 5.7% and net margin of 3.4% indicate structural margin pressure
- Extremely poor capital efficiency: ROE of 1.8% and ROA of 1.3% show inadequate returns on the 197.4M asset base
- Weak cash generation relative to capital intensity: FCF of 1.4M (1.8% margin) against 6.7M capex limits financial flexibility
- Cash position of 9.8M is minimal relative to revenue scale, leaving limited cushion for operational challenges
Key Metrics to Watch
- Operating margin expansion - critical to assess if growth translates to profitability
- Free cash flow generation and FCF conversion ratio - essential for debt reduction and reinvestment capacity
- Return on equity and return on assets trends - current 1.8% ROE and 1.3% ROA are unsustainably low
Viemed Healthcare, Inc.. (VMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 1.8% FCF margin may limit capital allocation flexibility.
VMD Profit Margin, ROE & Profitability Analysis
VMD vs Services Sector: How Viemed Healthcare, Inc.. Compares
How Viemed Healthcare, Inc.. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Viemed Healthcare, Inc.. Stock Overvalued? VMD Valuation Analysis 2026
Based on fundamental analysis, Viemed Healthcare, Inc.. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Viemed Healthcare, Inc.. Balance Sheet: VMD Debt, Cash & Liquidity
VMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Viemed Healthcare, Inc..'s revenue has grown significantly by 106% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.25 reflects profitable operations.
VMD Revenue Growth, EPS Growth & YoY Performance
VMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $59.1M | $2.6M | $0.06 |
| Q3 2025 | $58.0M | $3.5M | $0.09 |
| Q2 2025 | $55.0M | $1.5M | $0.04 |
| Q1 2025 | $50.6M | $1.6M | $0.04 |
| Q3 2024 | $49.4M | $2.9M | $0.07 |
| Q2 2024 | $43.3M | $1.5M | $0.04 |
| Q1 2024 | $39.6M | $1.5M | $0.04 |
| Q3 2023 | $35.8M | $967.0K | $0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Viemed Healthcare, Inc.. Dividends, Buybacks & Capital Allocation
VMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Viemed Healthcare, Inc.. (CIK: 0001729149)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VMD
What is the AI rating for VMD?
Viemed Healthcare, Inc.. (VMD) has an AI grade of B with 58% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VMD's key strengths?
Claude: Strong revenue growth at 20.5% YoY indicates solid market demand. Excellent balance sheet with minimal leverage (0.06x Debt/Equity) and adequate liquidity (1.22x current ratio).
What are the risks of investing in VMD?
Claude: Severely compressed profitability: operating margin of 5.7% and net margin of 3.4% indicate structural margin pressure. Extremely poor capital efficiency: ROE of 1.8% and ROA of 1.3% show inadequate returns on the 197.4M asset base.
What is VMD's revenue and growth?
Viemed Healthcare, Inc.. reported revenue of $75.4M.
Does VMD pay dividends?
Viemed Healthcare, Inc.. does not currently pay dividends.
Where can I find VMD SEC filings?
Official SEC filings for Viemed Healthcare, Inc.. (CIK: 0001729149) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VMD's EPS?
Viemed Healthcare, Inc.. has a diluted EPS of $0.06.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VMD's fundamental grade?
Based on our AI fundamental analysis in June 2026, Viemed Healthcare, Inc.. has a B grade with 58% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VMD stock overvalued or undervalued?
Valuation metrics for VMD: ROE of 1.8% (sector avg: 16%), net margin of 3.4% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
What is VMD's AI grade for 2026?
Our dual AI analysis gives Viemed Healthcare, Inc.. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VMD's free cash flow?
Viemed Healthcare, Inc..'s operating cash flow is $8.1M, with capital expenditures of $6.7M. FCF margin is 1.8%.
How does VMD compare to other Services stocks?
Vs Services sector averages: Net margin 3.4% (avg: 10%), ROE 1.8% (avg: 16%), current ratio 1.22 (avg: 1.5).